Acute myeloid leukemiaTherapy-Related Myeloid Leukemia
Section snippets
Subtypes of Therapy-Related Myeloid Leukemia
The characteristics of therapy-related leukemia and the timing of its development after a primary diagnosis depend on the exposure to specific agents, as well as the cumulative dose and dose intensity of the preceding cytotoxic therapy.
In the classic form of therapy-related leukemia that follows treatment with alkylating agents and/or radiation therapy, the blood and bone marrow findings resemble those seen in primary MDS, although the degree of dysgranulopoiesis and dysmegakaryocytopoiesis is
Risk Factors for the Development of Therapy-Related Leukemias
The etiology and specific factors that predispose to the development of therapy-related leukemia have been difficult to study. It has not yet been possible to determine whether the development of t-MDS/t-AML is a stochastic event, occurring by chance, or whether certain individuals are at higher risk. However, more recent studies have employed newer technology that allows the rapid sequencing of a large number of single nucleotide polymorphisms (SNPs) and suggest that at least a fraction of
Genetic Pathways and Cooperating Mutations in the Etiology of Therapy-Related Myeloid Leukemia
Particular mechanisms of DNA damage that lead either to chromosomal deletions or balanced translocations may underlie the differences in latencies between the two main forms of therapy-related leukemia.1, 27 In the case of chromosomal deletions, one allele of a putative tumor-suppressor gene may be inactivated. However, before the affected cell would gain a proliferative advantage, the second allele might have to be deleted or mutated also. In some cases, the first allele may be inactivated in
Therapy-Related Leukemia after Breast Cancer
Although long-term survivors of Hodgkin's disease were among the first patients to suffer the development of t-AML, this complication is now increasingly observed in those patients treated for solid tumors. Several large studies have examined the risks for women receiving adjuvant chemoradiotherapy for breast cancer. Several groups have addressed the question as to whether the addition of G-CSF to routine therapy regimens contributes to the risk of developing t-AML out of the concern that G-CSF
Therapy-Related Leukemia after Autologous Hematopoietic Cell Transplantation
Several thousand autotransplants are performed each year for patients with relapsed lymphoma and other diseases. Estimates of the incidence of therapy-related leukemia among these lymphoma and Hodgkin's disease patients range between 1% and 14% at 3 to 15 years.38 The risk appears lower in patients undergoing autologous hematopoietic cell transplantation (HCT) for breast or germ cell cancers or for myeloma. Important risk factors include age, extent of prior therapy, and exposure to certain
Factors That Influence Outcome in t-AML
Therapy-related myeloid leukemia is generally a fatal disease. The life-threatening complications of this disorder are the result of persistent and profound cytopenias due to the failure of normal hematopoiesis regardless of the fraction of myeloblasts accumulating in the bone marrow or blood. There has been general agreement that patients with t-AML have shorter survivals than patients with de novo AML. Supportive care is still considered by many to be the standard management.
A number of
Treatment of Therapy-Related Myeloid Leukemia
The survival of patients with therapy-related leukemia is often poor despite prompt diagnosis and treatment. However, there is a paucity of prospective treatment data since these patients are most often excluded from frontline clinical trials. There are no randomized studies comparing standard AML therapy to other forms of treatment. In a nationwide Japanese study of 256 patients with t-MDS (41%) or t-AML (59%), a poor prognosis was associated with abnormalities of chromosome 5,
HCT for t-AML
The treatment most likely to cure t-AML is allogeneic HCT. Several small case series have described the outcomes of these patients, and the survival rate appears to be about 20% to 30%.1, 42 However, chronic and cumulative toxicities from prior chemoradiotherapy have an impact on the ability to perform HCT and adversely affect survival. Early deaths from regimen-related toxicity are more common after HCT for therapy-related leukemia than for primary AML.
In an analysis of 70 patients (31 with
Treatment of t-AML With Balanced Chromosomal Rearrangements
In marked contrast to the poor outcome overall for t-AML, those patients who develop t-APL with t(15;17) or those with t(8;21) or inv(16) have response rates that are similar to patients with de novo AML with the same chromosomal rearrangements, although overall survival is less. In a report on 106 cases of t-APL identified between 1982 and 2001 in France, Spain, and Belgium, the characteristics of the t-APL patients were similar to those of de novo APL patients.46 In addition, more than 80% of
The Importance of Cytogenetic Abnormalities in Predicting Patient Outcomes
The most informative data on the prognostic impact of karyotype on outcome in t-AML were reported by the German AML Cooperative Group (AMLCG).49 This group compared karyotype analysis and survival between 93 patients with t-AML and 1,091 patients with de novo AML, all of whom received intensive treatment. Favorable, intermediate, and unfavorable karyotypes, respectively, were observed in 26%, 28%, and 46% of t-AML patients, and in 22%, 57%, and 20% of de novo AML patients. Overall, the median
Recommendations for Treatment of t-AML
Figure 3 shows a treatment algorithm for the management of patients who develop therapy-related myeloid leukemia. Primary considerations are the patient's performance status, which reflects age, comorbidities, the status of the primary disease, and the presence of complications from primary therapy, as well as the clonal abnormalities detected in the t-AML cells. In general, t-AML patients should be encouraged to participate in prospective clinical trials that are appropriately designed for
References (51)
- et al.
Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation
Blood
(2004) - et al.
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
Blood
(2003) - et al.
The World Health Organization (WHO) classification of the myeloid neoplasms
Blood
(2002) - et al.
Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy
Ann Oncol
(1999) - et al.
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
Blood
(2005) - et al.
Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab
Leuk Res
(2008) - et al.
Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
Blood
(1999) - et al.
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders
Blood
(2007) - et al.
Treatment of therapy-related leukemia and myelodysplastic syndrome
Hematol Oncol Clin North Am
(1993) - et al.
Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine
Blood
(1988)
Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy
Blood
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation
Biol Blood Marrow Transplant
The syndrome of therapy-related myelodysplasia and myeloid leukemia
International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report
Genes Chromosomes Cancer
Acute myeloid leukaemias and myelodysplastic syndromes, therapy related
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases
Blood
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map
Proc Natl Acad Sci U S A
Risk of leukemia after chemotherapy and radiation treatment for breast cancer
N Engl J Med
Melphalan may be a more potent leukemogen than cyclophosphamide
Ann Intern Med
Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop
Genes Chromosomes Cancer
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011
J Clin Oncol
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
J Clin Oncol
Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia
Br J Haematol
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia
Proc Natl Acad Sci U S A
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia
Clin Cancer Res
Cited by (252)
Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy
2023, European Journal of CancerMutation signatures reveal clonal evolution
2023, Blood
Supported in part by Grants No. CA40046 and CA14599 from the National Cancer Institute.